Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

Hair loss treatments and the user's plan to start using Pyrilutamide, a combination of Minoxidil and Finasteride.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Hair loss treatment using Fin, Minoxidil and RU58841 with discussion about potential side effects and the power of nocebo effect.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.

The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.

Switching from 1mg finasteride to dutasteride, with users recommending starting at 0.5mg daily. Some users prefer capsules, while others use tablets, citing effectiveness and regulatory approval in Asia.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.